Skip to main content
BioCentury on BioBusiness
Feature Story

Insights in interception

More details on Janssen's plans to intercept diseases like Type I diabetes

By Susan Schaeffer, Editor

Four months after launching an R&D group to predict and prevent progression to disease, Janssen Research & Development LLC has revealed the center's first research collaboration in Type I diabetes, named two new disease areas and shared additional details on how it is approaching disease interception.

Johnson & Johnson's Janssen unit established the Disease Interception Accelerator (DIA) in February to ring-fence resources for projects to identify at-risk populations in whom it might be possible to prevent the onset of disease. At the time, the DIA said its first research venture would focus on Type I diabetes.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial